(Boursier.com) — BioNTech the German partner of Pfizer, also listed on Wall Street, fell 9% in pre-trading on the US side. The lab today released its financial results for the second quarter, reporting revenue of 3.2 billion euros, net profit of 1.7 billion euros and earnings per share of 6, 45 euro. Over the first half as a whole, revenues were 9.6 billion euros, net profit was 5.4 billion euros and diluted EPS was 20.69 euros per share. The consensus was for more than 7 euros in quarterly earnings per share and nearly 4 billion euros in revenue. BioNTech nevertheless confirms its revenue estimates for the Covid-19 vaccine, ranging from 13 to 17 billion euros.
The group is preparing the potential launch of two bivalent Covid-19 vaccines adapted to variants containing the original strain and the spike protein Omicron BA.1 or BA.4/5, as recommended by the United States Food and Drug Administration (FDA) , the European Medicines Agency (EMA) and other regulators. BioNTech says it expects to be able to begin delivering suitable vaccines to Omicron as early as October 2022, subject to regulatory approval. The group highlights the signing of an agreement with the US government to provide an additional 105 million doses of Covid-19 vaccine with an option for an additional 195 million doses. It has also received US Emergency Use Authorization (EUA) for the Covid-19 vaccine in children six months to four years old and for a booster dose in children five to 11 years old. . BioNTech also highlights the continued expansion of the pipeline, as well as the start of construction of the first BioNTainer mRNA vaccine manufacturing facility in Africa.
“Based on our strong year-to-date performance, we believe we are on track to meet our previous financial guidance for the current fiscal year,” said Jens Holstein, BioNTech’s chief financial officer. “Thanks to our initiatives around variant-adapted Covid-19 vaccine candidates, we expect an increase in demand in our key markets in the fourth quarter of 2022”, adds the leader.
©2022 Boursier.com